Aidoc vs Qure AI
Two enterprise imaging AI companies built for different health systems, which is the useful way to read this pair. Aidoc is built for the well resourced hospital: an operating system handling normalisation, continuous performance monitoring and governance across many models, with a January 2026 clearance covering a double digit set of acute indications from one named foundation model and regulator reviewed performance behind it. Qure holds the broadest chest radiograph regulatory footprint in the market across nine products spanning radiography and computed tomography, and its deployments run where radiologist capacity is thinnest, including public health screening programmes. The comparison is not really about accuracy. It is about what the AI is compensating for. Aidoc reorders a worklist that a radiologist will read anyway. Qure is frequently the only read a patient will get, and those are different products with different consequences for a false negative.
- The infrastructure is the durable asset: normalisation, continuous performance monitoring and governance built into the platform so a health system can run many models without re architecting per algorithm.
- The January 2026 clearance covers a double digit set of acute indications from a single named foundation model, with performance figures from a regulator reviewed pivotal study rather than a vendor benchmark.
- The data handling model is published in unusual detail, with de identification performed before upload, which answers the privacy question architecturally rather than in a contract.
- The regulatory footprint across chest radiography is the broadest in the market, spanning nine products, with device dossiers published in the detail that European and other regulators require.
- It is built to work where radiologist capacity is scarce, including screening programmes in resource limited settings, which is a materially different deployment than a United States hospital worklist.
- On premise installation is supported and stated, which removes the data transfer question rather than governing it, and its cybersecurity documentation is reviewed inside its regulatory submissions rather than only by a commercial auditor.
Side by Side
| Axis | A Aidoc |
Q Qure AI |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The two records illustrate the non United States imaging pattern this index tracks: Qure publishes complete device regulatory dossiers and comparatively little United States health privacy or infosec material, because regulatory effort follows market access while privacy expectations are handled in contract.
A United States buyer should therefore ask Qure for the commercial assurance artifacts and a global buyer should ask Aidoc for the device dossiers, and each will find the other vendor stronger on their own axis. Neither publishes pricing. Prevalence also matters more here than either vendor says: identical sensitivity and specificity produce very different false positive burdens in a screening population than in an acute hospital one.